Information on suspected side effects now available through a single website

Information on suspected side effects, also known as suspected adverse drug reactions, of an additional 1,700 active substances contained in medicines approved in the European Union (EU) are now available through a website maintained by the European Medicines Agency (EMA),

Related content:

TOPRA signs up to the Science Council Diversity Declaration

On 6 October, Executive Director Lynda Wight was one of 16 CEOs of professional associations who signed up to the Science Council's Diversity Declaration.

Related content:

Human medicines highlights - Issue 67 - September 2014

The September 2014 issue of the European Medicines Agency's newsletter 'Human medicines highlights' is now available.

All issues of the newsletter are available on the Agency's website.

Related content:

Why earlier access requires earlier dialogue

TOPRA’s latest informal roundtable discussion – Parallel Scientific Advice with MHRA and NICE: what are the advantages and how does it work best? – took place on 24 September at the Royal Society in London. The discussion on parallel scientific advice, chaired by Dr Nick Sykes (Pfizer), attracted 25 senior TOPRA members and external guests who debated the workings and effectiveness of MHRA and NICE advice procedures available to companies developing new medicines.

Related content:

Steve Wratten – Director of Corporate Services

It is with great sadness that we announce the death of Steve Wratten, Director of Corporate Services for TOPRA.

Steve worked for us for over seven years and we valued his experience, clear thinking, direct style and utter commitment to the organisation.

Related content: